pamidronate has been researched along with Hyperparathyroidism, Secondary in 11 studies
Hyperparathyroidism, Secondary: Abnormally elevated PARATHYROID HORMONE secretion as a response to HYPOCALCEMIA. It is caused by chronic KIDNEY FAILURE or other abnormalities in the controls of bone and mineral metabolism, leading to various BONE DISEASES, such as RENAL OSTEODYSTROPHY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Secondary hyperparathyroidism may worsen after the administration of pamidronate in postmenopausal hemodialysis (HD) patients." | 9.16 | Effects of pamidronate and calcitriol on the set point of the parathyroid gland in postmenopausal hemodialysis patients with secondary hyperparathyroidism. ( Chu, P; Huang, CY; Lo, L; Lu, KC; Wu, CC; Zheng, CM, 2012) |
| "The aim of this study was to evaluate the efficacy and safety of pamidronate in HD patients affected by severe secondary hyperparathyroidism and moderate hypercalcemia who were receiving intravenous calcitriol (Calcijex)." | 9.10 | Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis. ( Fuster, D; Mas, M; Moreno, A; Torregrosa, JV; Ybarra, J, 2003) |
| "The purpose of this study is to evaluate the acute effect of pamidronate on plasma ionized calcium (iCa) level reduction and dynamic parathyroid hormone (PTH) secretion in postmenopausal hemodialysis-dependent women with secondary hyperparathyroidism." | 7.72 | Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism. ( Chu, P; Lin, SH; Lin, YF; Lu, KC; Yeung, LK, 2003) |
| "Secondary hyperparathyroidism may worsen after the administration of pamidronate in postmenopausal hemodialysis (HD) patients." | 5.16 | Effects of pamidronate and calcitriol on the set point of the parathyroid gland in postmenopausal hemodialysis patients with secondary hyperparathyroidism. ( Chu, P; Huang, CY; Lo, L; Lu, KC; Wu, CC; Zheng, CM, 2012) |
| "The aim of this study was to evaluate the efficacy and safety of pamidronate in HD patients affected by severe secondary hyperparathyroidism and moderate hypercalcemia who were receiving intravenous calcitriol (Calcijex)." | 5.10 | Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis. ( Fuster, D; Mas, M; Moreno, A; Torregrosa, JV; Ybarra, J, 2003) |
| "The purpose of this study is to evaluate the acute effect of pamidronate on plasma ionized calcium (iCa) level reduction and dynamic parathyroid hormone (PTH) secretion in postmenopausal hemodialysis-dependent women with secondary hyperparathyroidism." | 3.72 | Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism. ( Chu, P; Lin, SH; Lin, YF; Lu, KC; Yeung, LK, 2003) |
| "Calciphylaxis is a rare complication of chronic renal failure mostly with poor prognosis." | 1.36 | Skin wounds associated with calciphylaxis in end-stage renal disease patients on dialysis. ( Sulková, SD; Válek, M, 2010) |
| "Pamidronate was well tolerated; femoral neck fractures occurred in 2 subjects with severe local Paget's disease but were unlikely to be due to the drug." | 1.28 | Single-dose intravenous pamidronate is effective alternative therapy for Paget's disease refractory to calcitonin. ( Galligan, JP; Jacobi, JM; Khafagi, FA; Mortimer, RH; Perry-Keene, DA; Yap, AS, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, N | 1 |
| Reilly, RF | 1 |
| Huang, CY | 1 |
| Zheng, CM | 1 |
| Wu, CC | 1 |
| Lo, L | 1 |
| Lu, KC | 2 |
| Chu, P | 2 |
| Sulková, SD | 1 |
| Válek, M | 1 |
| ten Dam, MA | 1 |
| Hilbrands, LB | 1 |
| Wetzels, JF | 1 |
| Torregrosa, JV | 1 |
| Moreno, A | 1 |
| Mas, M | 1 |
| Ybarra, J | 1 |
| Fuster, D | 1 |
| Yeung, LK | 1 |
| Lin, SH | 1 |
| Lin, YF | 1 |
| Tokumoto, T | 1 |
| Tanabe, K | 1 |
| Toma, H | 1 |
| Akiba, T | 1 |
| Bains, MA | 1 |
| Pardoe, LE | 1 |
| Rudin, CE | 1 |
| Boyce, BF | 1 |
| Adamson, BB | 1 |
| Gallacher, SJ | 1 |
| Byars, J | 1 |
| Ralston, SH | 1 |
| Boyle, IT | 1 |
| Berruti, A | 1 |
| Sperone, P | 1 |
| Fasolis, G | 1 |
| Torta, M | 1 |
| Fontana, D | 1 |
| Dogliotti, L | 1 |
| Angeli, A | 1 |
| Yap, AS | 1 |
| Mortimer, RH | 1 |
| Jacobi, JM | 1 |
| Galligan, JP | 1 |
| Perry-Keene, DA | 1 |
| Khafagi, FA | 1 |
2 reviews available for pamidronate and Hyperparathyroidism, Secondary
| Article | Year |
|---|---|
Hungry bone syndrome.
Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitriol; Calcium; Diphosphonates; Hum | 2017 |
[Treatment of bone disease in chronic kidney disease and in renal transplant recipients under K/DOQI clinical practice guidelines].
Topics: Bone Density; Bone Diseases, Metabolic; Calcitonin; Chronic Disease; Diphosphonates; Epoxy Compounds | 2004 |
2 trials available for pamidronate and Hyperparathyroidism, Secondary
| Article | Year |
|---|---|
Effects of pamidronate and calcitriol on the set point of the parathyroid gland in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
Topics: Anti-Inflammatory Agents; Bone Density Conservation Agents; Calcitriol; Calcium; Calcium Channel Ago | 2012 |
Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis.
Topics: Aged; Bone Density; Diphosphonates; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; K | 2003 |
7 other studies available for pamidronate and Hyperparathyroidism, Secondary
| Article | Year |
|---|---|
Skin wounds associated with calciphylaxis in end-stage renal disease patients on dialysis.
Topics: Aged; Anti-Inflammatory Agents; Calciphylaxis; Cinacalcet; Diphosphonates; Female; Humans; Hyperpara | 2010 |
Nephrotic syndrome induced by pamidronate.
Topics: Adenocarcinoma; Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Huma | 2011 |
Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
Topics: Aged; Chronic Kidney Disease-Mineral and Bone Disorder; Diphosphonates; Female; Humans; Hypercalcemi | 2003 |
Osteitis fibrosa cystica and secondary hyperparathyroidism in multiple myeloma.
Topics: Antineoplastic Agents; Bone Marrow Cells; Diphosphonates; Female; Humans; Hyperparathyroidism, Secon | 2007 |
Mineralisation defects after pamidronate for Paget's disease.
Topics: Calcification, Physiologic; Diphosphonates; Humans; Hyperparathyroidism, Secondary; Osteitis Deforma | 1994 |
Pamidronate administration improves the secondary hyperparathyroidism due to "Bone Hunger Syndrome" in a patient with osteoblastic metastases from prostate cancer.
Topics: Aged; Alkaline Phosphatase; Bone and Bones; Bone Neoplasms; Calcium; Collagen; Diphosphonates; Human | 1997 |
Single-dose intravenous pamidronate is effective alternative therapy for Paget's disease refractory to calcitonin.
Topics: Aged; Calcitonin; Calcium; Diphosphonates; Drug Resistance; Female; Humans; Hyperparathyroidism, Sec | 1991 |